By: IPP Bureau
Last updated : December 23, 2025 7:31 pm
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has acquired full global rights for the adalimumab biosimilar Hulio from Fujifilm Kyowa Kirin Biologics (FKB).
This new agreement replaces their previous partnership, shifting complete control of manufacturing, commercialization, and future development to Biocon Biologics.
While Biocon Biologics will now manage end-to-end operations, FKB will continue to support development and offset specific costs in exchange for a technology license fee and ongoing royalties.
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited, said: "This agreement with FKB provides Biocon Biologics the manufacturing rights to biosimilar Adalimumab, granting us end-to-end control over the product. This strategic move enhances flexibility and cost efficiency, reinforcing our commitment to expanding affordable access to high-quality biologics for patients with inflammatory diseases globally."
Biocon Biologics initially acquired the commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris' global biosimilars business. Viatris had previously in-licensed the product from FKB. Under the earlier arrangement, FKB manufactures and supplies the product to Biocon Biologics, which holds global commercial rights for HULIO.
Adalimumab is one of the three immunology biosimilars in Biocon Biologics' overall portfolio, which underscores the company's strategic focus on expanding access to biologics for immune-mediated diseases worldwide.